Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Eaton Corporation plc (ETN) vs 10X Genomics Inc (TXG) Price & Performance

Eaton Corporation plcTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

Eaton Corporation plc vs 10X Genomics Inc — how do they compare? Eaton Corporation plc trades at $460.6 (market cap $172.82B), while 10X Genomics Inc trades at $57.2 (market cap $7.61B). The key difference: Eaton Corporation plc is far larger — about 22.7× 10X Genomics Inc's market cap, and Eaton Corporation plc pays a 0.99% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.

ETNTXG
Market Cap
$172.82B$7.61B
Sector
TechnologyHealth
52-Week High
$459.29$58.57
52-Week Low
$315.82$11.34
Enterprise Value
$193.45B$7.14B
Dividend Yield
0.99%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Eaton Corporation plc

Eaton Corporation (ETN) trades at $463.70, up 4.21% over the past 24 hours, near its 52-week high. The stock shows strong technical momentum with bullish moving averages and is approaching resistance at $467. Fundamentally, the company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $3.15 beating estimates of $3.07, and raised its full-year 2026 outlook. Revenue growth is robust, supported by surging data-center demand and a $7 million U.S. Air Force contract for grid security announced on August 6, 2026.

The outlook remains positive given Eaton's exposure to AI-driven power infrastructure spending, but the stock's premium valuation (P/E of 45.31) poses a risk if growth moderates. Analyst consensus is strongly bullish with a $499.75 price target, though investors should monitor execution risks and macroeconomic pressures that could impact the industrial sector.

10X Genomics Inc

TXG (10x Genomics) trades at $56.95, down 2.77% on the day. The stock exhibits bullish technical signals with strong moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and a narrowing net loss margin from -41.23% in 2023 to -12.18% in 2026. Recent news highlights collaborations with Cleveland Clinic and acquisition of Proteintech Genomics, expanding multiomics capabilities.

Outlook: Growth potential exists through market expansion and innovation, but risks include persistent unprofitability and high valuation multiples. Analyst sentiment is mixed with a $46 consensus target below current price, indicating caution despite recent operational improvements.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Eaton Corporation plc

Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.

Read more on ETN

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG